Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 2
2004 3
2005 3
2006 3
2007 1
2008 4
2009 6
2010 5
2011 6
2012 6
2013 7
2014 3
2015 17
2016 13
2017 9
2018 11
2019 12
2020 15
2021 13
2022 19
2023 10
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

146 results

Results by year

Filters applied: . Clear all
Page 1
A Cohort Study to Evaluate Genetic Predictors for Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS): Results from ECOG-ACRIN E1Z11.
Stearns V, Jegede OA, Chang VT, Skaar TC, Berenberg JL, Nand R, Shafqat A, Jacobs NL, Luginbuhl W, Gilman P, Benson AB, Goodman JR, Buchschacher GL, Henry NL, Loprinzi CL, Flynn PJ, Mitchell EP, Fisch MJ, Sparano JA, Wagner LI. Stearns V, et al. Among authors: skaar tc. Clin Cancer Res. 2024 Apr 19. doi: 10.1158/1078-0432.CCR-23-2137. Online ahead of print. Clin Cancer Res. 2024. PMID: 38640040
Nonlinear Mixed-Effects Model of Z-Endoxifen Concentrations in Tamoxifen-Treated Patients from the CEPAM Cohort.
Mc Laughlin AM, Helland T, Klima F, Koolen SLW, van Schaik RHN, Mathijssen RHJ, Neven P, Swen JJ, Guchelaar HJ, Dalenc F, White-Koning M, Michelet R, Mikus G, Schroth W, Mürdter T, Brauch H, Schwab M, Søiland H, Mellgren G, Thomas F, Kloft C, Hertz DL; CYP2D6 Endoxifen Percentage Activity Model (CEPAM) Consortium. Mc Laughlin AM, et al. Clin Pharmacol Ther. 2024 Mar 18. doi: 10.1002/cpt.3238. Online ahead of print. Clin Pharmacol Ther. 2024. PMID: 38494911
The INGENIOUS trial: Impact of pharmacogenetic testing on adverse events in a pragmatic clinical trial.
Eadon MT, Rosenman MB, Zhang P, Fulton CR, Callaghan JT, Holmes AM, Levy KD, Gupta SK, Haas DM, Vuppalanchi R, Benson EA, Kreutz RP, Tillman EM, Shugg T, Pierson RC, Gufford BT, Pratt VM, Zang Y, Desta Z, Dexter PR, Skaar TC. Eadon MT, et al. Among authors: skaar tc. Pharmacogenomics J. 2023 Nov;23(6):169-177. doi: 10.1038/s41397-023-00315-w. Epub 2023 Sep 9. Pharmacogenomics J. 2023. PMID: 37689822 Clinical Trial.
Patient understanding of pharmacogenomic test results in clinical care.
Doyle TA, Schmidt KK, Halverson CME, Olivera J, Garcia A, Shugg TA, Skaar TC, Schwartz PH. Doyle TA, et al. Among authors: skaar tc. Patient Educ Couns. 2023 Oct;115:107904. doi: 10.1016/j.pec.2023.107904. Epub 2023 Jul 17. Patient Educ Couns. 2023. PMID: 37531788
Computational pharmacogenotype extraction from clinical next-generation sequencing.
Shugg T, Ly RC, Osei W, Rowe EJ, Granfield CA, Lynnes TC, Medeiros EB, Hodge JC, Breman AM, Schneider BP, Sahinalp SC, Numanagić I, Salisbury BA, Bray SM, Ratcliff R, Skaar TC. Shugg T, et al. Among authors: skaar tc. Front Oncol. 2023 Jul 4;13:1199741. doi: 10.3389/fonc.2023.1199741. eCollection 2023. Front Oncol. 2023. PMID: 37469403 Free PMC article.
146 results